Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Philogen S.p.A.
AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Philogen CEO Dario Neri tells Scrip the company he co-founded now has two oncology products in Phase III development and might consider partnering them for certain indications.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Philochem AG